AV 1992CP
Alternative Names: AV-1992CPLatest Information Update: 28 Apr 2025
At a glance
- Originator Flinders University; Institute for Molecular Medicine; University of California at Irvine
- Developer Capo Therapeutics
- Class Alzheimer vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)